Spero Therapeutics Inc
NASDAQ:SPRO
Spero Therapeutics Inc
NASDAQ:SPRO
Price:
2.4
USD
4.35%
Market Closed
Market Cap:
$135.2m
Balance Sheet
Balance Sheet Decomposition
Spero Therapeutics Inc
Spero Therapeutics Inc
Balance Sheet Decomposition is not available for
Spero Therapeutics Inc
Spero Therapeutics Inc
Balance Sheet
Spero Therapeutics Inc
Spero Therapeutics Inc
Currency: USD
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
6
|
10
|
87
|
34
|
30
|
85
|
113
|
109
|
76
|
53
|
|
| Cash Equivalents |
6
|
10
|
87
|
34
|
30
|
85
|
113
|
109
|
76
|
53
|
|
| Short-Term Investments |
0
|
0
|
0
|
81
|
52
|
42
|
34
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
3
|
1
|
9
|
6
|
3
|
1
|
51
|
52
|
|
| Other Current Assets |
0
|
1
|
2
|
8
|
5
|
6
|
9
|
3
|
4
|
2
|
|
| Total Current Assets |
6
|
12
|
92
|
124
|
95
|
139
|
158
|
114
|
131
|
107
|
|
| PP&E Net |
1
|
2
|
1
|
3
|
7
|
9
|
8
|
6
|
4
|
3
|
|
| PP&E Gross |
1
|
2
|
1
|
3
|
7
|
9
|
8
|
6
|
4
|
3
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
2
|
2
|
3
|
3
|
4
|
4
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
47
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
2
|
4
|
5
|
6
|
6
|
0
|
0
|
|
| Total Assets |
7
N/A
|
14
+92%
|
94
+578%
|
129
+38%
|
106
-18%
|
154
+45%
|
171
+11%
|
125
-27%
|
182
+46%
|
111
-39%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
1
|
4
|
4
|
4
|
1
|
1
|
1
|
1
|
7
|
|
| Accrued Liabilities |
1
|
3
|
4
|
8
|
23
|
13
|
16
|
11
|
8
|
19
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
4
|
3
|
0
|
1
|
0
|
0
|
2
|
10
|
28
|
22
|
|
| Total Current Liabilities |
6
|
7
|
8
|
12
|
27
|
14
|
19
|
22
|
37
|
49
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
48
|
0
|
0
|
0
|
|
| Minority Interest |
1
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
1
|
0
|
1
|
5
|
7
|
16
|
27
|
38
|
15
|
|
| Total Liabilities |
7
N/A
|
4
-49%
|
9
+147%
|
14
+52%
|
32
+133%
|
21
-32%
|
83
+287%
|
49
-41%
|
75
+54%
|
64
-15%
|
|
| Equity | |||||||||||
| Common Stock |
18
|
56
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
18
|
45
|
97
|
139
|
199
|
278
|
368
|
414
|
391
|
460
|
|
| Additional Paid In Capital |
0
|
0
|
181
|
254
|
274
|
410
|
456
|
490
|
498
|
506
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
10
+5 000%
|
85
+729%
|
116
+37%
|
75
-35%
|
132
+77%
|
88
-33%
|
76
-14%
|
107
+41%
|
46
-57%
|
|
| Total Liabilities & Equity |
7
N/A
|
14
+92%
|
94
+578%
|
129
+38%
|
106
-18%
|
154
+45%
|
171
+11%
|
125
-27%
|
182
+46%
|
111
-39%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
14
|
14
|
14
|
17
|
19
|
29
|
32
|
53
|
53
|
55
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
3
|
3
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
